High energy intake and insulin levels, as well as increased sugar and candy consumption, are associated with lower disease activity in acute intermittent porphyria, a small population-based study suggests. The study, “Lifestyle factors including diet and biochemical biomarkers in acute intermittent porphyria: Results from a case-control study…
The ClpX protein recently has been studied for its role in causing erythropoietic protoporphyria (EPP). In a review study, researchers explored this connection and recommended further genetic studies. The study, “The role of ClpX in erythropoietic protoporphyria,” was published in the journal Hematology, Transfusion and Cell Therapy.
A genetic study found 19 new mutations in the…
Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to treat rare diseases has never been greater. That’s the paradox faced by pharmaceutical companies as well as patient advocacy groups in…
Nonconvulsive status epilepticus, a condition characterized by confusion, inability to speak, and diminished awareness, has been reported for the first time in a patient with variegate porphyria, according to a case study. The study, “Nonconvulsive status epilepticus secondary to acute Porphyria crisis,” was published in the journal,…
Genetic testing is vital to confirming the diagnosis of acute hepatic porphyria (AHP) in symptomatic patients, and identifying family members who carry mutations but have no symptoms, a study by Mount Sinai researchers — that found family mutations in 50 percent of the asymptomatic people tested — reports. The study, based on…
Canadian patients who have recurrent attacks of acute intermittent porphyria (AIP) can now be treated with Recordati Rare Diseases Canada’ injectable hemin formulation, Panhematin. Health Canada has approved the use of Panhematin to reduce the production and buildup of toxic compounds in the body induced by…
Results from a Phase 1 study and an open-label extension (OLE) trial have demonstrated that givosiran can effectively reduce attack rates and the use of hemin in patients with acute hepatic porphyria. The latest results of these clinical studies were recently discussed at The Liver Meeting 2018…
Three patients with multiple fat deposits in the liver caused by alcohol abuse were diagnosed with chronic hepatic porphyria (CHP), a case report describes. In all three cases, a highly sensitive imaging technique called contrast-enhanced ultrasound (CEUS) was useful in confirming a diagnosis. The report, “Multinodular…
Alnylam Pharmaceuticals, after consulting with the U.S. Food and Drug Administration, plans to pursue full approval of its lead therapy candidate, givosiran, for the treatment of acute hepatic porphyria (AHP), rather than accelerated approval. The full approval will be based on the complete results of the ongoing…
Get regular updates to your inbox.